FDA Grants Emergency Use Authorization to Eli Lilly COVID-19 Antibody Cocktail

The EUA is based on positive results from a Phase III trial that showed bamlanivimab and etesevimab together reduced the risk of COVID-19 hospitalizations and death by 70%.